Celltrion, Inc.
068270
Rank in Stocks
#720
Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the... Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.
Share Price
$146.63
Market Cap
$33.44B
Change (1 day)
-1.52%
Change (1 year)
23.60%
Country
KR
Trade Celltrion, Inc. (068270)
Category
Healthcare
EPS for Celltrion, Inc. (068270)
EPS as of June 2026 TTM: $5.22
According to Celltrion, Inc. latest financial reports and stock price the company's current EPS (TTM) is $5.22. At the end of 2024 the company had a EPS of $1.34 a decrease compared to its 2023 EPS that were of $2.66.
EPS history for Celltrion, Inc. from 2007 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $5.22 | 68.95% |
| 2025 | $3.09 | 130.81% |
| 2024 | $1.34 | -49.63% |
| 2023 | $2.66 | -13.83% |
| 2022 | $3.09 | 0.15% |
| 2021 | $3.08 | 2.06% |
| 2020 | $3.02 | 67.27% |
| 2019 | $1.80 | 18.18% |
| 2018 | $1.53 | -36.19% |
| 2017 | $2.39 | 161.38% |
| 2016 | $0.92 | 2.82% |
| 2015 | $0.89 | 17.76% |
| 2014 | $0.76 | 5.82% |
| 2013 | $0.71 | -40.03% |
| 2012 | $1.19 | 13.91% |
| 2011 | $1.05 | 42.90% |
| 2010 | $0.73 | 76.82% |
| 2009 | $0.41 | 330.46% |
| 2008 | $0.10 | -72.47% |
| 2007 | $0.35 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $17.32 | 231.76% |
US
|
|
| $-7.98 | -252.85% |
US
|
|
| $-5.29 | -201.33% |
AU
|
|
| $12.97 | 148.45% |
BE
|
|
| $27.74 | 431.35% |
NL
|
